project id: TCGA-PRAD; case submitter id: TCGA-VN-A943; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.81; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.69; rna integrity number: 8.9; age at index: 71; days to birth: -26162; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1942; age at diagnosis: 26162; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 496.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 139; initial weight: 40.0; sample id: 6cf3c393-09d1-49ca-a303-adf3e3622df7; sample submitter id: TCGA-VN-A943-01A; portion id: c44016e2-fbaa-4919-848f-741a7a3b42f8; portion submitter id: TCGA-VN-A943-01A-11; slide id: 6ce59d3f-3331-4314-b88d-2bdb10514fa0; slide submitter id: TCGA-VN-A943-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 5.0; percent stromal cells: 0.0; percent tumor cells: 95.0; percent tumor nuclei: 77.0; section location: TOP;